Cargando…

Maintenance therapy of low-dose nivolumab, S-1, and leucovorin in metastatic pancreatic adenocarcinoma with a germline mutation of MSH6: A case report

Immune checkpoint inhibitors (ICIs) provide substantial benefits to a small subset of patients with advanced cancer with mismatch repair deficiency (MMRD) or microsatellite instability (MSI), including patients with pancreatic ductal adenocarcinoma (PDAC). However, the long duration of ICI treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Peng, Shang-Hsuan, Chen, Bang-Bin, Kuo, Ting-Chun, Lee, Jen-Chieh, Yang, Shih-Hung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792834/ https://www.ncbi.nlm.nih.gov/pubmed/36582237 http://dx.doi.org/10.3389/fimmu.2022.1077840

Ejemplares similares

Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma
por: Yang, Shih-Hung, et al.
Publicado: (2022)

Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma
por: Yang, Shih-Hung, et al.
Publicado: (2021)

The role of nanoliposomal irinotecan plus fluorouracil/leucovorin in the continuum of care of patients with metastatic pancreatic ductal adenocarcinoma
por: Procaccio, Letizia, et al.
Publicado: (2023)

Clinical outcomes of liposomal irinotecan plus fluorouracil/leucovorin for metastatic pancreatic adenocarcinoma in patients previously treated with conventional irinotecan-containing chemotherapy
por: Bang, Kyunghye, et al.
Publicado: (2021)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Petrioli, R, et al.
Publicado: (2004)

UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Alliot, C
Publicado: (2004)

Reply: UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer
por: Francini, G, et al.
Publicado: (2004)

Treatment Options for Germline BRCA-Mutated Metastatic Pancreatic Adenocarcinoma
por: Grzelak, Doreen
Publicado: (2021)

Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan
por: Chen, Chia-Yu, et al.
Publicado: (2020)

Case report: Complete response to pembrolizumab in a liver metastatic colon adenocarcinoma patient with a novel likely pathogenic germline MSH2 mutation
por: Xu, Yanjie, et al.
Publicado: (2022)

Treatment of unresectable, locally advanced pancreatic adenocarcinoma with combined radiochemotherapy with 5-fluorouracil, leucovorin and cisplatin
por: Kornek, G V, et al.
Publicado: (2000)

Cost-Effectiveness Analysis of Olaparib Maintenance Treatment for Germline BRCA-Mutated Metastatic Pancreatic Cancer
por: Li, Na, et al.
Publicado: (2021)

Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients
por: Rashid, Muhammad Usman, et al.
Publicado: (2019)

Real-world efficacy and safety of liposomal irinotecan plus fluorouracil/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group
por: Yoo, Changhoon, et al.
Publicado: (2019)

Nomogram for Predicting Survival in Patients Treated with Liposomal Irinotecan Plus Fluorouracil and Leucovorin in Metastatic Pancreatic Cancer
por: Chen, Li-Tzong, et al.
Publicado: (2019)

Report of a germline double heterozygote in MSH2 and PALB2
por: Agiannitopoulos, Konstantinos, et al.
Publicado: (2020)

Loss or Somatic Mutations of hMSH2 Occur in Hereditary Nonpolyposis Colorectal Cancers with hMSH2 Germline Mutations
por: Lu, Shi‐Long, et al.
Publicado: (1996)

A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients
por: Hsu, Hung-Chih, et al.
Publicado: (2018)

Germline MLH1, MSH2 and MSH6 variants in Brazilian patients with colorectal cancer and clinical features suggestive of Lynch Syndrome
por: Schneider, Nayê Balzan, et al.
Publicado: (2018)

Parallel administration of nanoliposomal irinotecan and levo-leucovorin for pancreatic cancer
por: Takada, Ryoji, et al.
Publicado: (2023)

An Extremely Rapid Case of Pneumonitis with the Use of Nivolumab for Pancreatic Adenocarcinoma
por: Costa, Rubens Barros, et al.
Publicado: (2018)

In vivo Antitumor Effects of Fluoropyrimidines on Colon Adenocarcinoma 38 and Enhancement by Leucovorin
por: Iigo, Masaaki, et al.
Publicado: (1992)

Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer
por: Moehler, M, et al.
Publicado: (2005)

Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
por: Chen, Yi-Chieh, et al.
Publicado: (2021)

Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4)
por: Chen, Chin-Fan, et al.
Publicado: (2008)

Germline truncating mutations in both MSH2 and BRCA2 in a single kindred
por: Thiffault, I, et al.
Publicado: (2004)

Novel germline MSH2 mutation in lynch syndrome patient surviving multiple cancers
por: Janavicius, Ramunas, et al.
Publicado: (2012)

A Case of Perimenopausal Endometrial Cancer in a Woman with MSH2 Germline Mutation
por: Heo, Eun Jin, et al.
Publicado: (2013)

Case report of adrenocortical carcinoma associated with double germline mutations in MSH2 and RET
por: Raygada, Margarita, et al.
Publicado: (2021)

An isolated childhood myeloid sarcoma with germline MSH6 mutation—a case report
por: Liu, Yu, et al.
Publicado: (2021)

Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study
por: Hong, R L, et al.
Publicado: (1999)

Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib
por: Hammel, P, et al.
Publicado: (2019)

Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer
por: Koizumi, W., et al.
Publicado: (2010)

Low-dose nivolumab in advanced hepatocellular carcinoma
por: Chen, Yen-Hao, et al.
Publicado: (2022)

HGG-21. GERMLINE MUTATIONS IN MSH2 GENE IN PEDIATRIC PATIENTS WITH CONGENITAL AND SPORADIC GLIOBLASTOMA
por: Ejmont, Maria, et al.
Publicado: (2020)

Pleomorphic rhabdomyosarcoma in a young adult harboring a novel germline MSH2 variant
por: Tomida, Akimasa, et al.
Publicado: (2022)

An MSH6 germline pathogenic variant p.Gly162Ter associated with Lynch syndrome
por: Vostrukhina, Olga A., et al.
Publicado: (2022)

Somatic Hypermutation in Muts Homologue (Msh)3-, Msh6-, and Msh3/Msh6-Deficient Mice Reveals a Role for the Msh2–Msh6 Heterodimer in Modulating the Base Substitution Pattern
por: Wiesendanger, Margrit, et al.
Publicado: (2000)

Alternating irinotecan with oxaliplatin combined with UFT plus leucovorin (SCOUT) in metastatic colorectal cancer
por: Sheikh, H Y, et al.
Publicado: (2008)

Combination of oxaliplatin, fluorouracil, and leucovorin in the treatment of fluoropyrimidine-pretreated patients with metastatic colorectal cancer.
por: Lee, J. H., et al.
Publicado: (2001)

Cannot write session to /tmp/vufind_sessions/sess_jbn09fasdq5p03j1v28nh2rcd9